Clinical trials: Herpes Simplex, Genital
HIV Infections, Chlamydia Trachomatis
Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months.
- Conditions
- HIV Infections, Chlamydia Trachomatis, Neisseria Gonorrhoeae, Trichomonas Vaginitis
- Trial name
- NCT00213031
- Testing
- Carraguard (PC-515)
- Where
- Thailand
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Population Council
Herpes Simplex, HIV Infections
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Trial name
- NCT00002000
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 22 sites in United States
- Sponsor
- Glaxo Wellcome
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
HSV-2
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
- Trial name
- NCT01047540
- Testing
- AIC316
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- AiCuris Anti-infective Cures AG
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex, HIV Infections
Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir
To compare the safety and effectiveness of foscarnet and vidarabine treatments for AIDS patients who have herpes simplex virus infections that are resistant to standard treatment with acyclovir.
- Trial name
- NCT00000985
- Testing
- Vidarabine, Acyclovir, Foscarnet sodium
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Simplex, HIV Infections
The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients
The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes.
- Trial name
- NCT00002404
- Testing
- Valacyclovir hydrochloride
- Volunteers
- 30 people
- Sponsor
- Glaxo Wellcome
Herpes Simplex, HIV Infections
The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood
Part A: To evaluate the impact of HSV suppression with acyclovir ( ACV ) on HIV burden in patients with asymptomatic HSV infection and at high risk for HSV reactivation.
- Trial name
- NCT00001115
- Testing
- Acyclovir
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Herpesvirus 2, Human
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time.
- Trial name
- NCT00371592
- Testing
- Acyclovir
- Where
- Peru
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Simplex, HIV Infections
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for refractory mucocutaneous herpes simplex virus disease in AIDS patients.
- Trial name
- NCT00002116
- Testing
- Cidofovir
- Where
- 9 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Bacterial Vaginosis, Herpes Simplex Virus Type II
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2.
- Trial name
- NCT00682721
- Testing
- Valacyclovir
- Where
- United States
- Sponsor
- University of Pittsburgh
Herpes Zoster, Shingles
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Trial name
- NCT01132716
- Testing
- Valacyclovir Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Herpes Simplex
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
This study will evaluate the effectiveness of the drug valaciclovir in preventing transmission of genital herpes from an infected to an uninfected sexual partner.
- Trial name
- NCT00001649
- Testing
- Valaciclovir
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Genital Herpes
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no…
- Trial name
- NCT00723229
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Genital Herpes
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
- Trial name
- NCT03595995
- Testing
- UB-621
- Volunteers
- 80 people
- Sponsor
- United BioPharma
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin